Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types. Robert D. Schreiber, PhD | Investigator Matthew Gubin, PhD | Bridge Scholar Related Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Focus Tumor Antigen Discovery: Targeting Cancer Announcement, Press Release PICI Appoints John Connolly as Chief Scientific Officer Research Project CANDEL: A first-of-its-kind data analysis engine for scientific discovery Cancer Research Heroes, Partner Highlight A Science-Driven Partnership Announcement Our Stance on Equality Cancer Research Heroes The Power of Patient Samples Research Project REVIVE: Can we outsmart cancer by learning from the past? Announcement, Press Release PICI Appoints Frederic Pla as Chief Operating Officer